Group One Trading, L.P. Aeglea Bio Therapeutics, Inc. Transaction History

Group One Trading, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$0.11 - $0.46 $254 - $1,062	-2,310 Reduced 80.15%	572 $0
Q1 2023 May 12, 2023	SELL	$0.29 - $0.61 $87 - $183	-300 Reduced 9.43%	2,882 $0
Q4 2022 Feb 09, 2023	BUY	$0.35 - $1.54 $28 - $126	82 Added 2.65%	3,182 $1,000
Q2 2022 Aug 11, 2022	BUY	$0.5 - $2.66 $50 - $266	100 Added 3.33%	3,100 $2,000
Q1 2022 May 12, 2022	SELL	$1.87 - $4.77 $4,301 - $10,970	-2,300 Reduced 43.4%	3,000 $7,000
Q4 2021 Feb 11, 2022	BUY	$3.5 - $8.42 $18,550 - $44,626	5,300 New	5,300 $25,000
Q3 2021 Nov 12, 2021	SELL	$6.03 - $7.95 $1,809 - $2,385	-300 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$6.32 - $8.38 $632 - $838	100 Added 50.0%	300 $2,000
Q4 2020 Feb 10, 2021	BUY	$7.02 - $9.83 $702 - $983	100 Added 100.0%	200 $2,000
Q3 2020 Nov 12, 2020	BUY	$6.51 - $9.33 $651 - $933	100 New	100 $1,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.